Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide for Cognitive Improvement in Down Syndrome (Children and Adolescents)
2024-519342-71-00Phase 2Authorised
- Sponsor
- Ospedale Pediatrico Bambino Gesù
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Down syndrome comparing Bumetanide (Burinex) with Placebo (2 arms). Planned start Feb 2025; status: authorised.
02
Drugs
bumetanide
03
Conditions
Down syndrome
Beyond the preview
Go deeper on 2024-519342-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519342-71-00.